Hemangiol, Post Marketing Surveillance Study (postHemangiol)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04105517|
Recruitment Status : Recruiting
First Posted : September 26, 2019
Last Update Posted : September 26, 2019
Infantile hemangioma is a benign tumor belonging to the group of vascular tumors in the ISSVA classification (International Society for the Study of Vascular Anomalies). The diagnosis is clinical and radiological. The hemangioma appears during the first weeks of life (70% classically within 2 weeks after birth) but can, when it develops in the subcutaneous tissue, appear until the age of 2 to 3 months .
Its evolution is characteristic and is divided into 3 phases with a proliferative phase characterized by a rapid increase in the size of the tumor (up to 6 to 12 months), a phase of stabilization (from 12 to 36 months) with a stopping of the growth of the hemangioma and a regression of its size and a phase of involution with the disappearance of the lesion which may give way to residual fibroadipose tissue, cutaneous telangiectases, scars … The usual complications of haemangiomas occur during the proliferative phase. It is necrosis, ulcerations that can be complicated by bleeding or infection and eventually indelible scarring. Other complications related to the site of development of hemangiomas (amblyopia, astigmatism, upper respiratory obstruction, nasal obstruction, sphincter disorders, eating disorders), hemangiomas destroying structures noble (breast hypodévelopment, alopecia). The aesthetic prognosis can be seriously compromised for facial locations.
Historically, when drug therapy was required, patient management was based on systemic corticosteroids (at doses of 3 to 5 mg / kg / day) in first-line therapy and vincristine as a second-line failure of corticosteroid therapy or when life-threatening is at stake.
In 2014, the high French health authority (HAS) gave Marketing Authorization for Hemangiol 3.75 mg / ml oral solution for the management of infantile proliferative hemangioma requiring first-line systemic treatment, evaluating the actual benefit as important.
The selected indication concerns children from 5 weeks to 5 months with:
- Hemangiomas leading to a vital or functional risk,
- Hemangiomas ulcerated painful and / or not responding to simple care,
- Hemangiomas with a risk of permanent scarring or disfigurement. The 2014 HAS Transparency Commission wishes in its report "to have follow-up data of prescriptions allowing to describe on a representative sample of patients, the characteristics of the treated patients, the indication, the doses and the durations of treatment of this specialty ".
The objective of our study is to describe the use of Hemangiol in current practice in our hospital from 2014 to 2018.
|Condition or disease|
This study is retrospective, longitudinal, descriptive and observational. Children aged 0 to 1 years hospitalized for introduction of Hemangiol between January 2014 and November 2018 will be included. Patients refuse the use of medical data will be excluded.
The main objective is to describe the population who received Hemangiol. The secondary objectives is to evaluate
- the effectiveness of Hemangiol on proliferative infantile hemangiomas, -the tolerance of Hemangiol in children with proliferative infantile hemangiomas
- the interest of systematic cardiological consultation in children with proliferative infantile hemangiomas receiving Hemangiol
The following criteria will be collected
Demographic description: age, sex, height, weight
Description of the hemangioma:
- organ concerned: skin, liver, parotid, mixed.
- location: head, thorax, pelvis, limbs, diffuse ...
- single or multiple
- indication of treatment: aesthetic, functional, ulcerated, cardiac hyperacidity
Rhythm of follow-up: duration of treatment and observance of treatment
Prescribed dose: 1, 2, 3 or 4 mg / kg / day in 2 doses
Evolution of the hemangioma: progression, regression, stagnation. Needed a second medical therapeutic line by specifying the treatment introduced. Necessity of surgical management by specifying the delay between surgery and the introduction of treatment
Description of serious adverse events: hypotension, bradycardia, bronchospasm, hypoglycaemia. Description of other adverse events.
Number of cardio-pediatric consultations, specifying:
- incidence of diagnosed heart disease through systematic cardiac consultation
- effect on ECG data of increasing dosage of Hemangiol: heart rate, PR duration, QRS duration, QT duration
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Prescription of Hemangiol in the Treatment of Proliferative Infantile Hemangiomas Requiring Systemic Treatment: Post Marketing Surveillance Study|
|Actual Study Start Date :||July 1, 2019|
|Estimated Primary Completion Date :||October 20, 2019|
|Estimated Study Completion Date :||October 30, 2019|
- Incidence of adverse events in children with proliferative infantile hemangiomas receiving Hemangiol [ Time Frame: 6 days ]
- rate serious adverse events: hypotension, bradycardia, bronchospasm, hypoglycemia
- rate of adverse events
- Incidence of the regression of proliferative infantile hemangiomas in children receiving Hemangiol [ Time Frame: 6 days ]
rate of regression of the hemangioma
- rate of need for a second therapeutic medical line
- rate of need for surgical management
- Incidence of diagnosed heart diseases with systematic cardiac consultation events in children with proliferative infantile hemangiomas receiving Hemangiol [ Time Frame: 3 days ]rate of diagnosed heart disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04105517
|Contact: Pascal AMEDRO, MD, PhD||0467336632 ext email@example.com|
|Montpellier, France, 34295|
|Contact: Arthgur GAVOTTO, MD 04 67 33 66 32 ext 33 firstname.lastname@example.org|
|Principal Investigator:||Arthur GAVOTTO, MD||University Hospital, Montpellier|